Cizzle Biotechnology Holdings PLC Update on Development of Proprietary Antibodies (2826R)
July 05 2022 - 1:00AM
UK Regulatory
TIDMCIZ
RNS Number : 2826R
Cizzle Biotechnology Holdings PLC
05 July 2022
This announcement contains inside information for the purposes
of article 7 of EU Regulation 596/2014 which forms part of domestic
UK law pursuant to the European Union (Withdrawal) Act 2018 ("UK
MAR") . Upon the publication of this announcement this inside
information is now considered to be within the public domain.
5 July 2022
Cizzle Biotechnology Holdings Plc
("Cizzle Biotechnology" or the "Company")
Update on the Development of Proprietary Antibodies for
Early-Stage Lung Cancer Detection Tests and Initial Indications in
Detecting Other Cancers
Cizzle Biotechnology, the UK based diagnostics developer, is
pleased to provide an update on the Company's progress to develop
antibodies for use in its proprietary early lung cancer tests, and
to announce a new project that may extend the range of early-stage
cancers that its technology can detect, with a focus initially on
breast cancer.
Highlights
-- Monoclonal antibody ("mAb") to CIZ1B now in assay optimisation
-- mAb reporter protein developed and ready for test development
-- mAb supplier agreements extended to increase use case diversity
-- Work initiated to extend use case to breast cancer
Background
Cizzle Biotechnology is developing a blood test for the early
detection of lung cancer. Its technology is based on the ability to
detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B.
CIZ1 is a naturally occurring cell nuclear protein involved in DNA
replication, and the targeted CIZ1B variant is highly correlated
with early-stage lung cancer.
On 22 July 2021 the Company announced a collaboration with
FairJourney Biologics ("FJB") for the development and supply of
proprietary key monoclonal antibodies and other detector proteins
that are required for developing an enzyme-linked immunosorbent
assay (sandwich "ELISA"). Since that time the Company has
significantly increased its knowledge on reagent performance and
assay formats and is pleased to announce that monoclonal reporter
antibodies have been successfully produced by FJB
The Company also recognises that it is important to develop a
range of monoclonal antibodies to detect CIZ1B and additional
suppliers have been engaged. The Company is pleased to report that
it has a mouse monoclonal antibody that specifically detects CIZ1B
and that assay conditions for its use are now being optimised.
Further work is being done to isolate rabbit monoclonals arising
from the Company's initial proof of concept studies.
In parallel, new projects have been initiated to evaluate the
use of CIZ1B for the detection of other cancers, which has led to
an initial focus on breast cancer, which could widen the utility of
this important cancer biomarker.
According to World Cancer Research Fund International, lung
cancer is the second most common cancer worldwide, and the most
common cancer in men and the second most common cancer in women. In
total t here were more than 2.2 million new cases of lung cancer in
2020*. Breast cancer is the most commonly occurring cancer in women
and the most common cancer overall. There were more than 2.26
million new cases of breast cancer in women worldwide in 2020.
Survival rates vary for different cancers and it is accepted that
progress in the early detection, and so early treatment of cancer,
can led to a dramatic increase in the number of cancer
survivors.
* Lung cancer statistics | World Cancer Research Fund
International (wcrf.org)
Commenting, Allan Syms, Executive Chairman of Cizzle
Biotechnology, said:
"It is an unfortunate fact that in the UK alone every two
minutes someone is diagnosed with cancer**. That is compounded by
the fact that in its early stage, cancer can be asymptomatic and
remain undetected until the disease has advanced, lowering survival
rates. Simple, inexpensive, blood tests for early cancer detection
can help save lives. The recent progress made in developing these
tests at Cizzle Biotechnology, not just for lung cancer, but for a
range of other cancers is a significant step forward in our
ambitions to provide the right tools to improve cancer patient
outcomes."
** Cancer Statistics for the UK (cancerresearchuk.org)
Enquiries:
Cizzle Biotechnology Holdings Via IFC Advisory
plc
Allan Syms (Executive Chairman)
Allenby Capital Limited +44(0) 20 33285656
John Depasquale
Alex Brearley
Novum Securities Limited +44(0) 20 7399 9400
Colin Rowbury
Jon Bellis
IFC Advisory Limited +44(0) 20 3934 6630
Tim Metcalfe cizzle@investor-focus.co.uk
Florence Chandler
Notes to Editors:
About Cizzle Biotechnology
Cizzle Biotechnology is developing a blood test for the early
detection of lung cancer. Cizzle Biotechnology is a spin- out from
the University of York, founded in 2006 around the work of
Professor Coverley and colleagues . Its proof-of-concept prototype
test is based on the ability to detect a stable plasma biomarker, a
variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell
nuclear protein involved in DNA replication, and the targeted CIZ1B
variant is highly correlated with early-stage lung cancer.
For more information, please see
https://cizzlebiotechnology.com
You can also follow the Company through its twitter account
@CizzlePlc and on LinkedIn.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDDZGGNRDVGZZM
(END) Dow Jones Newswires
July 05, 2022 02:00 ET (06:00 GMT)
Cizzle Biotechnology (LSE:CIZ)
Historical Stock Chart
From Apr 2024 to May 2024
Cizzle Biotechnology (LSE:CIZ)
Historical Stock Chart
From May 2023 to May 2024